120245-33-2

Basic information

• Product Name: Thiophene, 3-[2-(phenylmethoxy)ethyl]-
• CAS NO: 120245-33-2
• Molecular Formula: C13H14OS
• Molecular Weight: 218.32
• Mol File: 120245-33-2.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Thiophene, 3-[2-(phenylmethoxy)ethyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Thiophene, 3-[2-(phenylmethoxy)ethyl]-(120245-33-2)
• EPA Substance Registry System: Thiophene, 3-[2-(phenylmethoxy)ethyl]-(120245-33-2)

Safety Data

• Hazardous Substances Data: 120245-33-2(Hazardous Substances Data)

Upstream product

• 13781-67-4 3-(2-hydroxyethyl)thiophene 
• 100-39-0 benzyl bromide 
• 1462-37-9 bromoethyl-2-benzyl ether 
• 872-31-1 3-Bromothiophene 
• 1408168-73-9 potassium [2-(benzyloxy)ethyl]-trifluoroboranuide 
• 14861-60-0 1-(thiophen-3-yl)ethan-1-ol 

Downstream Products

• 717927-48-5 C₁₃H₁₃ClO₃S₂ 

Relevant articles and documents

Rational synthesis of regioregular oligothiophenes via palladium catalyzed coupling reactions

The synthesis of bis-, ter-, quater- and sexithiophenes using Stille methodology allows a controlled thiophene chain elongation.

SUBSTITUTED 1-PIPERIDIN-4-YL-4-PYRROLIDIN-3-YL-PIPERAZINE DERIVATIVES AND THEIR USE AS NEUROKININ ANTAGONISTS

This invention concerns substituted I-piperidin-4-yl-4-pyrrolidin-3-yl-piperazine derivatives having neurokinin antagonistic activity, in particular NK1 antagonistic activity, a combined NK1/NK3 antagonistic activity and a combined NK1/NK2/NK3 antagonistic activity, their preparation, compositions comprising them and their use as a medicine, in particular for the treatment of schizophrenia, anxiety, depression, emesis and IBS. The compounds according to the invention can be represented by general Formula (I) and comprises also the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the N-oxide form thereof and prodrugs thereof, wherein all substituents are defined as in Claim 1. In view of their capability to antagonize the actions of tachykinins by blocking the neurokinin receptors, and in particular antagonizing the actions of substance P and Neurokinin B by blocking the NK1, NK2 and NK3 receptors, the compounds according to the invention are useful as a medicine, in particular in the prophylactic and therapeutic treatment of tachykinin-mediated conditions, such as, for instance CNS disorders, in particular schizoaffective disorders, depression, anxiety disorders, stress-related disorders, sleep disorders, cognitive disorders, personality disorders, eating disorders, neurodegenerative diseases, addiction disorders, mood disorders, sexual dysfunction, pain and other CNS-related conditions ; inflammation ; allergic disorders ; emesis ; gastrointestinal disorders, in particular irritable bowel syndrome (IBS); skin disorders ; vasospastic diseases ; fibrosing and collagen diseases ; disorders related to immune enhancement or suppression and rheumatic diseases and body weight control.